Publications by authors named "Rose Ajamie"

Claim this Profile
P
Pharmacokinetic and screening studies of the interaction between mononuclear phagocyte system and nanoparticle formulations and colloid forming drugs.
Andrew T Lucas, Leah B Herity, Zack A Kornblum, Andrew J Madden, Alberto Gabizon, Rose T Ajamie

Int J Pharm· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.
Michele C Smith, Mary M Mader, James A Cook, Philip Iversen, Rose Ajamie

Mol Cancer Ther· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Thomas J Raub, Graham N Wishart, Palaniappan Kulanthaivel, Brian A Staton, Rose T Ajamie

Drug Metab Dispos· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
Lawrence M Gelbert, Shufen Cai, Xi Lin, Concepcion Sanchez-Martinez, Miriam Del Prado, Rose T Ajamie

Invest New Drugs· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts.
Sonya C Tate, Shufen Cai, Rose T Ajamie, Teresa Burke, Richard P Beckmann

Clin Cancer Res· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models.
Tinggui Yin, Maria J Lallena, Emiko L Kreklau, Kevin R Fales, Santiago Carballares, Rose T Ajamie

Mol Cancer Ther· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
S Betty Yan, Victoria L Peek, Rose Ajamie, Sean G Buchanan, Jeremy R Graff

Invest New Drugs· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs.
Maciej J Zamek-Gliszczynski, Kenneth J Ruterbories, Rose T Ajamie, Enaksha R Wickremsinhe, Lavanya Pothuri

J Pharm Sci· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
James R Henry, Yihong Li, Alan M Warshawsky, Joseph T Brozinick, Eric D Hawkins, Rose T Ajamie

Bioorg Med Chem Lett· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis